Wordt geladen...
Ex Vivo Virotherapy With Myxoma Virus Does Not Impair Hematopoietic Stem and Progenitor Cells
BACKGROUND: Relapsing disease is a major challenge after hematopoietic cell transplant for hematological malignancies. Myxoma virus (MYXV) is an oncolytic virus that can target and eliminate contaminating cancer cells from auto-transplant grafts. The aims of this study were to examine the impact of...
Bewaard in:
| Gepubliceerd in: | Cytotherapy |
|---|---|
| Hoofdauteurs: | , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4748395/ https://ncbi.nlm.nih.gov/pubmed/26857235 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcyt.2015.12.007 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|